



Condensed Consolidated Balance Sheets

(in millions)	2017				2018				2019
	Unaudited				Unaudited				Unaudited
	1Q 17	2Q 17	3Q 17	4Q 17	1Q 18	2Q 18	3Q 18	4Q 18	1Q 19
ASSETS									
Current assets:									
Cash and cash equivalents	\$ 981	\$ 1,219	\$ 1,354	\$ 1,225	\$ 1,560	\$ 1,344	\$ 1,346	\$ 1,144	\$ 2,270
Short-term investments	797	674	687	920	813	1,168	2,043	2,368	1,345
Accounts receivable, net	368	372	383	411	400	395	433	514	457
Inventory	299	309	327	333	350	362	374	386	412
Prepaid expenses and other current assets	72	69	54	91	71	68	66	78	61
Total current assets	2,517	2,643	2,805	2,980	3,194	3,337	4,262	4,490	4,545
Property and equipment, net	734	837	862	931	983	1,036	1,060	1,075	852
Operating lease right-of-use assets	-	-	-	-	-	-	-	-	574
Goodwill	771	771	771	771	775	831	831	831	831
Intangible assets, net	207	196	185	175	168	205	195	185	175
Deferred tax assets, net	83	103	117	88	100	108	86	70	87
Other assets	286	308	306	312	322	334	325	308	326
Total assets	\$ 4,598	\$ 4,858	\$ 5,046	\$ 5,257	\$ 5,542	\$ 5,851	\$ 6,759	\$ 6,959	\$ 7,390
LIABILITIES AND STOCKHOLDERS' EQUITY									
Current liabilities:									
Accounts payable	\$ 142	\$ 175	\$ 158	\$ 160	\$ 151	\$ 149	\$ 156	\$ 184	\$ 137
Accrued liabilities	386	378	381	432	388	422	450	513	473
Build-to-suit lease liability	192	124	124	144	21	21	22	-	-
Long-term debt, current portion	1	5	2	10	620	625	1,107	1,107	631
Total current liabilities	721	682	665	746	1,180	1,217	1,735	1,804	1,241
Operating lease liabilities	-	-	-	-	-	-	-	-	718
Long-term debt	1,055	1,169	1,180	1,182	710	723	860	890	1,112
Other long-term liabilities	212	212	222	360	364	343	352	359	212
Redeemable noncontrolling interest	59	80	124	220	215	217	218	61	37
Stockholders' equity	2,551	2,715	2,855	2,749	3,073	3,351	3,594	3,845	4,070
Total liabilities and stockholders' equity	\$ 4,598	\$ 4,858	\$ 5,046	\$ 5,257	\$ 5,542	\$ 5,851	\$ 6,759	\$ 6,959	\$ 7,390



Condensed Consolidated Statements of Income

(in millions, except per share amounts and %)	2017					2018					2019	
	Unaudited					Unaudited					Unaudited	
	1Q 17	2Q 17	3Q 17	4Q 17	FY 17	1Q 18	2Q 18	3Q 18	4Q 18	FY 18	1Q 19	
Revenue:												
Product revenue	\$ 491	\$ 543	\$ 596	\$ 659	\$ 2,289	\$ 628	\$ 673	\$ 710	\$ 738	\$ 2,749	\$ 667	
Service and other revenue	107	119	118	119	463	154	157	143	129	584	179	
Total revenue	598	662	714	778	2,752	782	830	853	867	3,333	846	
Cost of revenue:												
Cost of product revenue	166	168	173	172	679	174	181	184	198	738	182	
Cost of service and other revenue	53	50	50	55	208	62	65	62	70	260	71	
Amortization of acquired intangible assets	11	10	9	9	39	8	9	10	9	35	9	
Total cost of revenue	230	228	232	236	926	244	255	256	277	1,033	262	
Gross profit	368	434	482	542	1,826	538	575	597	590	2,300	584	
Operating expense:												
Research and development	145	130	134	137	546	137	151	159	176	623	169	
Selling, general and administrative (b)	171	161	167	175	674	183	197	197	217	794	211	
Total operating expense	316	291	301	312	1,220	320	348	356	393	1,417	380	
Income from operations	52	143	181	230	606	218	227	241	197	883	204	
Other income (expense), net	451	(2)	(6)	(6)	437	3	5	(9)	13	11	29	
Income before income taxes	503	141	175	224	1,043	221	232	232	210	894	233	
Provision for income taxes	155	21	23	166	365	24	32	44	12	112	9	
Consolidated Net income	348	120	152	58	678	197	200	188	198	782	224	
Net loss attributable to noncontrolling interests	19	8	11	10	48	11	9	11	12	44	9	
Net income attributable to Illumina stockholders	\$ 367	\$ 128	\$ 163	\$ 68	\$ 726	\$ 208	\$ 209	\$ 199	\$ 210	\$ 826	\$ 233	
Net income attributable to Illumina stockholders for earnings per share	\$ 366	\$ 128	\$ 163	\$ 68	\$ 725	\$ 208	\$ 209	\$ 199	\$ 210	\$ 826	\$ 233	
Earnings per share attributable to Illumina Stockholders (a):												
Basic	\$2.50	\$0.87	\$1.12	\$0.47	\$4.96	\$1.42	\$1.42	\$1.35	\$1.43	\$5.63	\$1.58	
Diluted	\$2.48	\$0.87	\$1.11	\$0.46	\$4.92	\$1.41	\$1.41	\$1.33	\$1.41	\$5.56	\$1.57	
Shares used in computing earnings per common share:												
Basic	146	146	146	146	146	147	147	147	147	147	147	
Diluted	147	147	148	148	148	148	148	149	149	149	149	
Gross Margin	62%	66%	68%	70%	66%	69%	69%	70%	68%	69%	69%	
R&D as % of revenue	24%	20%	19%	18%	20%	18%	18%	19%	20%	19%	20%	
SG&A as % of revenue	29%	24%	24%	23%	25%	23%	24%	23%	25%	24%	25%	
Operating Expenses as % of revenue	53%	44%	42%	40%	44%	41%	42%	42%	45%	43%	45%	
Operating Margin	9%	22%	25%	30%	22%	28%	27%	28%	23%	26%	24%	
Tax Rate	31%	15%	13%	74%	35%	11%	14%	19%	6%	13%	4%	

All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided.

(a) Our consolidated VIEs' losses are included in the Company's consolidated basic and diluted earnings per share computations based on Illumina's weighted average common shares as a percentage of the VIEs' weighted average common shares.

(b) Legal contingencies of \$8M and \$(8)M for Q1 2017 and Q2 2017, respectively, were reclassified to selling, general and administrative expenses.



Non-GAAP Data

Unaudited

See "Reconciliation GAAP-non-GAAP" tabs within this workbook for reconciliations of the non-GAAP financial measures to GAAP

	2017					2018					2019	
	1Q 17	2Q 17	3Q 17	4Q 17	FY 17	1Q 18	2Q 18	3Q 18	4Q 18	FY 18	1Q 19	
(in millions, except per share amounts and %)												
Revenue	\$ 598.2	\$ 662.4	\$ 714.0	\$ 777.7	\$ 2,752.3	\$ 782.0	\$ 830.3	\$ 853.4	\$ 866.8	\$ 3,332.5	\$ 845.6	
Gross profit	397.2	443.7	491.3	551.4	1,883.5	546.1	583.5	606.6	599.2	2,335.4	593.2	
Research and development expense	139.5	130.4	133.7	135.0	538.6	136.7	150.7	158.7	175.9	622.0	168.9	
Selling, general and administrative expense	153.2	166.6	165.9	172.2	658.0	179.0	196.7	196.9	212.4	785.4	194.6	
Income from operations	104.5	146.6	191.6	244.1	686.8	230.4	236.1	251.0	210.9	928.1	229.7	
Consolidated net income	81.4	113.4	152.3	201.9	549.0	203.3	203.0	215.6	184.3	806.2	228.5	
Net loss attributable to noncontrolling interests	12.8	7.9	10.9	10.2	41.8	10.7	9.5	11.2	12.5	43.9	8.5	
Net income attributable to Illumina stockholders	94.2	121.3	163.3	212.1	590.8	214.0	212.5	226.8	196.8	850.1	237.0	
Diluted EPS attributable to Illumina stockholders	0.64	0.82	1.11	1.44	4.00	1.45	1.43	1.52	1.32	5.72	1.60	
Helix and GRAIL dilution (benefit)	0.07	0.05	0.07	0.06	0.25	(0.04)	0.03	0.05	0.05	0.09	0.05	
Tax rate	24.4%	25.1%	21.6%	18.0%	21.5%	12.9%	15.9%	17.3%	16.3%	15.6%	8.7%	

All amounts in tables are rounded to the nearest one hundred thousands, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided.



Reconciliation Between GAAP and Non-GAAP Net Income and Earnings Per Share Attributable to Illumina Stockholders
Unaudited

(in millions, except per share amounts)	2017					2018					2019
	1Q 17	2Q 17	3Q 17	4Q 17	FY 17	1Q 18	2Q 18	3Q 18	4Q 18	FY 18	1Q 19
GAAP earnings per share attributable to Illumina stockholders - diluted	\$ 2.48	\$ 0.87	\$ 1.11	\$ 0.46	\$ 4.92	\$ 1.41	\$ 1.41	\$ 1.33	\$ 1.41	\$ 5.56	\$ 1.57
Costs of revenue (b)	0.20	0.07	0.06	0.06	0.39	0.05	0.06	0.07	0.06	0.23	0.06
Research and development costs (b)	0.03	-	-	0.01	0.04	-	-	-	-	0.01	-
Selling, general, and administrative costs (b)	0.09	(0.05)	0.01	0.03	0.07	0.03	-	-	0.03	0.06	0.12
Other (income) expense, net (b)	(3.04)	0.05	0.06	0.05	(2.88)	-	-	0.13	(0.02)	0.12	(0.06)
Incremental non-GAAP tax expense (c)	0.93	(0.03)	(0.05)	(0.05)	0.80	(0.02)	(0.02)	(0.05)	(0.01)	(0.10)	(0.03)
Income tax (benefit) expense (b)	(0.05)	(0.09)	(0.08)	0.88	0.66	(0.02)	(0.02)	0.04	(0.15)	(0.16)	(0.06)
Non-GAAP earnings per share attributable to Illumina stockholders - diluted (a)	\$ 0.64	\$ 0.82	\$ 1.11	\$ 1.44	\$ 4.00	\$ 1.45	\$ 1.43	\$ 1.52	\$ 1.32	\$ 5.72	\$ 1.60
GAAP net income attributable to Illumina stockholders	\$ 367	\$ 128	\$ 163	\$ 68	\$ 726	\$ 208	\$ 209	\$ 199	\$ 210	\$ 826	\$ 233
Costs of revenue (b)	29	10	9	9	57	8	9	10	9	35	9
Research and development costs (b)	5	-	-	2	7	-	-	-	-	1	-
Selling, general, and administrative costs (b)	13	(6)	2	3	11	4	-	-	5	9	17
Other (income) expense, net (b)	(448)	7	9	8	(425)	-	-	19	(3)	17	(9)
Incremental non-GAAP tax expense (c)	136	(5)	(8)	(7)	117	(3)	(3)	(7)	(2)	(15)	(4)
Income tax (benefit) expense (b)	(8)	(13)	(12)	129	98	(3)	(3)	6	(22)	(23)	(9)
Non-GAAP net income attributable to Illumina stockholders (a)	\$ 94	\$ 121	\$ 163	\$ 212	\$ 591	\$ 214	\$ 212	\$ 227	\$ 197	\$ 850	\$ 237

All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided.

(a) Non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders exclude the effect of the pro forma adjustments as detailed above. Non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance.

(b) Refer to our "Reconciliation between GAAP and Non-GAAP Results of Operations" and "Reconciliation between GAAP and Non-GAAP Tax Provision," for the components of these amounts.

(c) Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed.



Reconciliation Between GAAP and Non-GAAP Results of Operations
Unaudited

(in millions)	2017					2018					2019
	1Q 17	2Q 17	3Q 17	4Q 17	FY 17	1Q 18	2Q 18	3Q 18	4Q 18	FY 18	1Q 19
GAAP gross profit	\$ 368	\$ 434	\$ 482	\$ 542	\$ 1,826	\$ 538	\$ 575	\$ 597	\$ 590	\$ 2,300	\$ 584
Amortization of acquired intangible assets	11	10	9	9	39	8	9	10	9	35	9
Impairment	18	-	-	-	18	-	-	-	-	-	-
Non-GAAP gross profit (a)	\$ 397	\$ 444	\$ 491	\$ 551	\$ 1,883	\$ 546	\$ 584	\$ 607	\$ 599	\$ 2,335	\$ 593
GAAP research and development expense	\$ 145	\$ 130	\$ 134	\$ 137	\$ 546	\$ 137	\$ 151	\$ 159	\$ 176	\$ 623	\$ 169
Restructuring (b)	-	-	-	(2)	(2)	-	-	-	-	(1)	-
Impairment	(5)	-	-	-	(5)	-	-	-	-	-	-
Non-GAAP research and development expense	\$ 140	\$ 130	\$ 134	\$ 135	\$ 539	\$ 137	\$ 151	\$ 159	\$ 176	\$ 622	\$ 169
GAAP selling, general and administrative expense (c)	\$ 171	\$ 161	\$ 167	\$ 175	\$ 674	\$ 183	\$ 197	\$ 197	\$ 217	\$ 794	\$ 211
Amortization of acquired intangible assets	(2)	(2)	(2)	(1)	(6)	(1)	-	-	-	(2)	(1)
Acquisition-related gain (expense), net (d)	1	-	-	-	1	-	-	-	(2)	(2)	(16)
Performance-based compensation related to GRAIL series B financing (e)	(10)	-	-	-	(10)	-	-	-	-	-	-
Legal contingencies	(8)	8	-	-	-	-	-	-	-	-	-
Restructuring (b)	-	-	-	(2)	(2)	(3)	-	-	(3)	(5)	-
Non-GAAP selling, general and administrative expense	\$ 152	\$ 167	\$ 165	\$ 172	\$ 657	\$ 179	\$ 197	\$ 197	\$ 212	\$ 785	\$ 194
GAAP operating profit	\$ 52	\$ 143	\$ 181	\$ 230	\$ 606	\$ 218	\$ 227	\$ 241	\$ 197	\$ 883	\$ 204
Costs of revenue	29	10	9	9	57	8	9	10	9	35	9
Research and development costs	5	-	-	2	7	-	-	-	-	1	-
Selling, general, and administrative costs	19	(6)	2	3	17	4	-	-	5	9	17
Non-GAAP operating profit (a)	\$ 105	\$ 147	\$ 192	\$ 244	\$ 687	\$ 230	\$ 236	\$ 251	\$ 211	\$ 928	\$ 230
GAAP other income (expense), net	\$ 451	\$ (2)	\$ (6)	\$ (6)	\$ 437	\$ 3	\$ 5	\$ (9)	\$ 13	\$ 11	\$ 29
Non-cash interest expense	7	8	8	8	30	8	7	11	15	41	14
Strategic investment related (gain) loss, net	(2)	(1)	1	-	(2)	(8)	(7)	8	(18)	(24)	(8)
Gain on deconsolidation of GRAIL (f)	(453)	-	-	-	(453)	-	-	-	-	-	(15)
Non-GAAP other income (expense), net (a)	\$ 3	\$ 5	\$ 3	\$ 2	\$ 12	\$ 3	\$ 5	\$ 10	\$ 10	\$ 28	\$ 20

All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided.

(a) Non-GAAP gross profit, included within non-GAAP operating profit, is a key measure of the effectiveness and efficiency of manufacturing processes, product mix and the average selling prices of the company's products and services. Non-GAAP operating profit, and non-GAAP other income (expense), net, exclude the effects of the pro forma adjustments as detailed above. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future operating performance.

(b) Amount consists primarily of employee and lease exit costs related to the restructuring that occurred in Q1 2018 and Q4 2017.

(c) Legal contingencies of \$8M and \$(8)M for Q1 2017 and Q2 2017, respectively, were reclassified to selling, general and administrative expenses.

(d) Amount for 2019 and 2018 consists of acquisition-related expenses related to the pending Pacific Biosciences acquisition. Amount for 2017 consists of changes in fair value of contingent consideration.

(e) Amount represents performance-based stock which vested as a result of the financing in Q1 2017. The impact to net income and diluted earnings per share attributable to Illumina stockholders presented in our "Reconciliation Between GAAP and Non-GAAP Net Income and Earnings Per Share Attributable to Illumina Stockholders" is net of attribution to noncontrolling interests.

(f) Amount represents additional gain resulting from the settlement of a contingency related to the deconsolidation of GRAIL in 2017.



Reconciliation Between GAAP and Non-GAAP Tax Provision

Unaudited

	2017					2018					2019
	1Q 17	2Q 17	3Q 17	4Q 17	FY 17	1Q 18	2Q 18	3Q 18	Q4 18	FY18	1Q 19
(in millions, except percentages)											
GAAP tax provision %	30.8%	15.2%	12.9%	74.1%	35.0%	10.6%	13.9%	19.0%	5.8%	12.5%	3.9%
GAAP tax provision	\$ 155	\$ 21	\$ 23	\$ 166	\$ 365	\$ 24	\$ 32	\$ 44	\$ 12	\$ 112	\$ 9
Incremental non-GAAP tax expense (a)	(138)	5	8	7	(117)	3	3	7	2	15	4
Excess tax benefit from share-based compensation (b)	8	13	12	21	52	3	3	5	22	34	9
U.S. Tax Reform (c)	-	-	-	(150)	(150)	-	-	(11)	-	(11)	-
Non-GAAP tax provision	\$ 25	\$ 39	\$ 43	\$ 44	\$ 150	\$ 30	\$ 38	\$ 45	\$ 36	\$ 150	\$ 22
Non-GAAP tax provision %	24.4%	25.1%	21.6%	18.0%	21.5%	12.9%	15.9%	17.3%	16.3%	15.6%	8.7%

All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided.

(a) Incremental non-GAAP tax expense reflects the tax impact related to the non-GAAP adjustments listed in our "Reconciliation Between GAAP and Non-GAAP Net Income and Earnings Per Share Attributable to Illumina Stockholders".

(b) Amount represents tax deductions taken in excess of stock compensation cost.

(c) In accordance with the Tax Cuts and Jobs Act enacted on December 22, 2017 (U.S. Tax Reform), amount for 2017 primarily represents the provisional estimate of the one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and the impact of revaluing our U.S. deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. The 2018 amount represents the discrete tax expense associated with updating prior year estimates of the impact of U.S. Tax Reform.

Condensed Consolidated Statements of Cash Flows

	2017					2018					2019
	Unaudited					Unaudited					Unaudited
(in millions)	1Q 17	2Q 17	3Q 17	4Q 17	FY 17	1Q 18	2Q 18	3Q 18	Q4 18	FY18	1Q 19
Net cash provided by operating activities	\$ 168	\$ 178	\$ 235	\$ 294	\$ 875	\$ 255	\$ 295	\$ 292	\$ 300	\$ 1,142	\$ 198
Net cash (used in) provided by investing activities	163	36	(97)	(315)	(214)	12	(536)	(940)	(349)	(1,813)	988
Net cash (used in) provided by financing activities	(86)	23	(5)	(109)	(176)	67	30	650	(153)	594	(60)
Effect of exchange rate changes on cash and cash equivalents	1	1.0	2	1	5	1	(5)	-	-	(4)	-
Net (decrease) increase in cash and cash equivalents	246	238	135	(129)	490	335	(216)	2	(202)	(81)	1,126
Cash and cash equivalents, beginning of period	735	981	1,219	1,354	735	1,225	1,560	1,344	1,346	1,225	1,144
Cash and cash equivalents, end of period	\$ 981	\$ 1,219	\$ 1,354	\$ 1,225	\$ 1,225	\$ 1,560	\$ 1,344	\$ 1,346	\$ 1,144	\$ 1,144	\$ 2,270
Calculation of free cash flow:											
Net cash provided by operating activities	\$ 168	\$ 178	\$ 235	\$ 294	\$ 875	\$ 255	\$ 295	\$ 292	\$ 300	\$ 1,142	\$ 198
Purchases of property and equipment	(83)	(69)	(82)	(76)	(310)	(90)	(77)	(64)	(65)	(296)	(56)
Free cash flow (a)	\$ 85	\$ 109	\$ 153	\$ 218	\$ 565	\$ 165	\$ 218	\$ 228	\$ 235	\$ 846	\$ 142

(a) Free cash flow, which is a non-GAAP financial measure, is calculated as net cash provided by operating activities reduced by purchases of property and equipment. Free cash flow is useful to management as it is one of the metrics used to evaluate our performance and to compare us with other companies in our industry. However, calculation of free cash flow may not be comparable to similar measures used by other companies.



Revenue by Geographic Region
Unaudited

	2017					2018					2019
(in millions)	1Q 17	2Q 17	3Q 17	4Q 17	FY 17	1Q 18	2Q 18	3Q 18	4Q 18	FY 18	1Q 19
REVENUE BY GEOGRAPHIC REGION (a)											
AMR	\$ 345	\$ 391	\$ 417	\$ 433	\$ 1,586	\$ 440	\$ 466	\$ 474	\$ 484	\$ 1,864	\$ 473
EMEA	130	148	165	210	653	194	202	219	236	851	210
GREATER CHINA (a)	56	78	87	71	292	78	107	102	77	365	88
APJ	67	45	45	64	221	70	55	58	70	253	75
Total Revenue	\$ 598	\$ 662	\$ 714	\$ 778	\$ 2,752	\$ 782	\$ 830	\$ 853	\$ 867	\$ 3,333	\$ 846

All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided.

(a) Revenue for the Greater China region, which consists of China, Taiwan, and Hong Kong, is reported separately from the APJ region.



Supplementary Data
Unaudited (a)

	2017					2018					2019
(in millions)	1Q 17	2Q 17	3Q 17	4Q 17	FY 17	1Q 18	2Q 18	3Q 18	4Q 18	FY 18	1Q 19
CONSUMABLES											
Sequencing Consumables	\$ 322	\$ 342	\$ 384	\$ 436	\$ 1,484	\$ 422	\$ 460	\$ 472	\$ 470	\$ 1,824	\$ 481
Microarrays Consumables	69	64	71	82	287	88	85	83	96	353	75
Total Consumables	391	406	455	518	1,771	510	545	555	566	2,177	556
% Revenue	65%	61%	64%	67%	64%	65%	66%	65%	65%	65%	66%
INSTRUMENTS											
Sequencing Instruments	\$ 95	\$ 131	\$ 129	\$ 132	\$ 487	\$ 112	\$ 124	\$ 138	\$ 161	\$ 535	\$ 105
Microarrays Instruments	5	6	12	9	31	6	4	17	11	37	6
Total Instruments	100	137	141	141	518	118	128	155	172	572	111
% Revenue	17%	21%	20%	18%	19%	15%	15%	18%	20%	17%	13%
TOTAL PRODUCT REVENUE	\$ 491	\$ 543	\$ 596	\$ 659	\$ 2,289	\$ 628	\$ 673	\$ 710	\$ 738	\$ 2,749	\$ 667
SERVICE & OTHER											
Sequencing	78	77	80	87	322	96	106	109	104	416	113
Microarrays	29	42	38	32	141	58	51	34	25	168	66
Total Service & Other	107	119	118	119	463	154	157	143	129	584	179
% Revenue	18%	18%	17%	15%	17%	20%	19%	17%	15%	18%	21%
TOTAL REVENUE	\$ 598	\$ 662	\$ 714	\$ 778	\$ 2,752	\$ 782	\$ 830	\$ 853	\$ 867	\$ 3,333	\$ 846

	2017					2018					2019
(in millions)	1Q 17	2Q 17	3Q 17	4Q 17	FY 17	1Q 18	2Q 18	3Q 18	4Q 18	FY 18	1Q 19
SEQUENCING											
Consumables	\$ 322	\$ 342	\$ 384	\$ 436	\$ 1,484	\$ 422	\$ 460	\$ 472	\$ 470	\$ 1,824	\$ 481
Instruments	95	131	129	132	487	112	124	138	161	535	105
Service & Other	78	77	80	87	322	96	106	109	104	416	113
Total Sequencing	\$ 495	\$ 550	\$ 593	\$ 655	\$ 2,293	\$ 630	\$ 690	\$ 719	\$ 735	\$ 2,775	\$ 699
% Revenue	83%	83%	83%	84%	83%	81%	83%	84%	85%	83%	83%
MICROARRAYS											
Consumables	\$ 69	\$ 64	\$ 71	\$ 82	\$ 287	\$ 88	\$ 85	\$ 83	\$ 96	\$ 353	\$ 75
Instruments	5	6	12	9	31	6	4	17	11	37	6
Service & Other	29	42	38	32	141	58	51	34	25	168	66
Total Microarrays	\$ 103	\$ 112	\$ 121	\$ 123	\$ 459	\$ 152	\$ 140	\$ 134	\$ 132	\$ 558	\$ 147
% Revenue	17%	17%	17%	16%	17%	19%	17%	16%	15%	17%	17%

All amounts in tables are rounded to the nearest millions, except as otherwise noted. As a result, certain amounts may not recalculate using the rounded amounts provided.

(a) Beginning in fiscal 2019, instruments and consumables revenue includes freight, which was presented as other product revenue in prior periods. Accordingly, prior period results have been reclassified to conform to this presentation.